Edition:
United Kingdom

Denali Therapeutics Inc (DNLI.OQ)

DNLI.OQ on NASDAQ Stock Exchange Global Select Market

20.82USD
19 Jul 2019
Change (% chg)

-- (--)
Prev Close
$20.82
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
150,092
52-wk High
$28.84
52-wk Low
$12.36

Latest Key Developments (Source: Significant Developments)

Denali Therapeutics Says Collaboration Revenue Was $4.2 Mln For Three Months Ended March 31, 2019
Wednesday, 8 May 2019 

May 8 (Reuters) - Denali Therapeutics Inc ::DENALI THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.DENALI THERAPEUTICS - COLLABORATION REVENUE WAS $4.2 MILLION FOR 3 MONTHS ENDED MARCH 31, 2019, VERSUS $0.6 MILLION FOR 3 MONTHS ENDED MARCH 31, 2018.COLLABORATION REVENUE WAS $4.2 MILLION FOR THREE MONTHS ENDED MARCH 31, 2019.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES WERE $583.0 MILLION AS OF MARCH 31, 2019..QTRLY LOSS PER SHARE $0.41.Q2 EARNINGS PER SHARE VIEW $-0.46, REVENUE VIEW $3.9 MILLION -- REFINITIV IBES DATA.  Full Article

Denali Therapeutics Inc Reports Q4 EPS Of $0.79
Tuesday, 12 Mar 2019 

March 12 (Reuters) - Denali Therapeutics Inc ::DENALI THERAPEUTICS REPORTS FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.DENALI THERAPEUTICS INC QTRLY NET INCOME OF $77.5 MILLION COMPARED WITH NET LOSS FOR Q4 DECEMBER 31, 2017 OF $22.9 MILLION.DENALI THERAPEUTICS INC - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES WERE $612.2 MILLION AS OF DECEMBER 31, 2018.DENALI THERAPEUTICS INC QTRLY EARNINGS PER SHARE $0.79.  Full Article

Denali Therapeutics Reports Qtrly Net Loss Per Share $0.74
Monday, 19 Mar 2018 

March 19 (Reuters) - Denali Therapeutics Inc ::DENALI THERAPEUTICS ANNOUNCES FIRST-IN-HUMAN DOSING OF ITS RIPK1 INHIBITOR CLINICAL PROGRAM AND THE APPOINTMENT OF PETER KLEIN TO BOARD OF DIRECTORS; REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.DENALI THERAPEUTICS INC - QTRLY NET LOSS PER SHARE $0.74.  Full Article

Takeda And Denali Therapeutics Collaborate To Develop Therapies For Neurodegenerative Diseases
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA AND DENALI THERAPEUTICS COLLABORATE TO DEVELOP AND COMMERCIALIZE THERAPIES FOR NEURODEGENERATIVE DISEASES.DENALI THERAPEUTICS - TAKEDA TO MAKE AN INITIAL PAYMENT TO CO OF $150 MILLION THROUGH COMBINATION OF CASH UPFRONT PAYMENTS AND PURCHASE OF DENALI EQUITY.DENALI THERAPEUTICS - TO BE RESPONSIBLE FOR DEVELOPMENT ACTIVITIES AND COSTS PRIOR TO IND FILING FOR EACH OF THREE PROGRAMS.DENALI - WILL BE ELIGIBLE TO RECEIVE DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS, INCLUDING $90 MILLION IN PRECLINICAL MILESTONES & OPT-IN PAYMENTS.DENALI THERAPEUTICS - COLLABORATION AGREEMENT TO DEVELOP,COMMERCIALIZE UP TO 3 SPECIFIED THERAPEUTIC PRODUCT CANDIDATES FOR NEURODEGENERATIVE DISEASES.DENALI - TAKEDA, CO WILL JOINTLY COMMERCIALIZE PRODUCTS IN U.S., CHINA, TAKEDA WILL HAVE EXCLUSIVE COMMERCIALIZATION RIGHTS IN ALL OTHER MARKETS.DENALI THERAPEUTICS - TAKEDA, CO WILL SHARE GLOBAL PROFITS FROM COLLABORATION EQUALLY.DENALI THERAPEUTICS INC - TAKEDA HAS OPTION TO CO-DEVELOP AND CO-COMMERCIALIZE EACH OF THREE PROGRAMS.  Full Article

Denali Therapeutics Announces Advancement And Expansion Of Its LRRK2 Inhibitor Clinical Program For Parkinson’S Disease
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Denali Therapeutics Inc ::DENALI THERAPEUTICS ANNOUNCES ADVANCEMENT AND EXPANSION OF ITS LRRK2 INHIBITOR CLINICAL PROGRAM FOR PARKINSON’S DISEASE.DENALI THERAPEUTICS - BASED ON REVIEW OF CLINICAL DATA FROM ONGOING STUDY ON LRRK2 INHIBITOR, FDA REMOVED PARTIAL CLINICAL HOLD.DENALI THERAPEUTICS SAYS PLANS TO SELECT EITHER DNL201 OR DNL151 TO MOVE INTO STUDIES IN PARKINSON'S DISEASE PATIENTS CARRYING A LRRK2 MUTATION.  Full Article

Denali Therapeutics Shares Open At $21.55 In Debut On The Nasdaq, about 20 pct above IPO price
Friday, 8 Dec 2017 

Dec 8 (Reuters) - :DENALI THERAPEUTICS SHARES OPEN AT $21.55 IN DEBUT ON THE NASDAQ VERSUS IPO PRICE OF $18.00/SHARE.  Full Article

Denali Therapeutics Says Initial Public Offering Of 13.9 Mln Common Shares Priced At $18 per Share
Friday, 8 Dec 2017 

Dec 7 (Reuters) - Denali Therapeutics Inc ::DENALI THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING.SAYS INITIAL PUBLIC OFFERING OF 13.9 MILLION COMMON SHARES PRICED AT $18.00PER SHARE.  Full Article

Denali Therapeutics Now Sees IPO Of 13.9 Million Shares Priced Between $17-$19 Per Share
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Denali Therapeutics Inc ::DENALI THERAPEUTICS INC SEES IPO OF 13.9 MILLION SHARES OF ITS COMMON STOCK PRICED BETWEEN $17.00 AND $19.00 PER SHARE - SEC FILING.DENALI THERAPEUTICS HAD PREVIOUSLY EXPECTED IPO OF 8.3 MILLION SHARES OF ITS COMMON STOCK PRICED BETWEEN $17-$19 PER SHARE.  Full Article

Denali Therapeutics sees IPO price range of $17.00-$19.00/shr
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Denali Therapeutics Inc ::DENALI THERAPEUTICS INC - SEES IPO OF 8.3 MILLION SHARES PRICED BETWEEN $17.00 AND $19.00 PER SHARE - SEC FILING‍​.  Full Article